Skip to main content

Table 1 Clinical characteristics of HCC patients and normal controls for serum analyses

From: CD5L-associated gene analyses highlight the dysregulations, prognostic effects, immune associations, and drug-sensitivity predicative potentials of LCAT and CDC20 in hepatocellular carcinoma

 

HCC (n = 50)

Normal (n = 30)

P

Age (y)

32–75; median:53

34–77; median:54

0.724

Gender (male/female)

44/6

24/6

0.518

AFP (ng/ml)

7.3–121,000; median: 650.95

0.860–6.360; median: 3.295

9.428E-14**

ALB (g/l)

18.6–49.7; median: 36.90

41.5–51.3; median: 45.80

3.6E-11**

HDL (mmol/l)

0.360–1.600; median:1.025

0.660–1.850; median:1.325

0.000138**

Tumor stage (I/II /III /IV)

5/14/22/9

  
  1. **p < 0.01. Chi-square test and Wilcoxon test were used for comparisons and p < 0.05 was considered significant
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us